With Am­gen hot on its heels, Ra­dius races to get a jump on os­teo­poro­sis drug ri­val­ry

This week, Ra­dius Health $RDUS will open a brand new chap­ter in its his­to­ry, armed with an FDA ap­proval for its os­teo­poro­sis drug Tym­los (abaloparatide).

Ra­dius is launch­ing its very first drug on­to the mar­ket, about to set the price on their ther­a­py (that ar­rives ear­ly Mon­day) and map­ping out a com­mer­cial strat­e­gy that will have to take in­to ac­count Eli Lil­ly’s ag­ing For­teo with the ri­val ro­mosozum­ab from Am­gen and UCB be­ing steered in­to a Ju­ly 19 PDU­FA date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER